Dogwood Q2 Loss Widens to $11.5M on $6.7M Impairment; Cash Runway to Q4 Readout
DWTX sits 41% above its 52-week low of $1.28.
Summary
Dogwood reported a Q2 net loss of $11.5 million, or $0.34 per share, versus a narrower loss a year ago, driven by a $6.7 million non-cash impairment charge tied to goodwill and IPR&D after a market cap decline. R&D spending rose on the Halneuron Phase 2b CINP study, and G&A increased on higher salaries and franchise fees. Cash of $9.6 million is expected to fund operations through the Phase 2b readout in Q4 2026, with top-line results due in fall 2026. The company also plans to begin enrolling the SP16 study for chemotherapy-induced pain in H2 2026. This follows the Q1 10-Q that showed a narrowed loss and extended runway, but the impairment and wider loss mark a setback. The key near-term event is the Halneuron Phase 2b data in fall 2026, which will determine whether the pipeline justifies the current valuation.
Updates
· SEC 10-Q — The 10-Q states cash is not sufficient to fund operations for at least 12 months and substantial doubt exists about Dogwood's ability to continue as a going concern.
At the time of this announcement, DWTX was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.7M. The 52-week trading range was $1.28 to $9.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.